Journal of clinical lipidology最新文献

{"title":"Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agents.","authors":"Eliana Elizabeth Botta, Florencia Pierini, Maximiliano Martin, Osvaldo Cerda, Ezequiel Lozano Chiappe, Gustavo Citera, Belén Davico, Ignacio Gandino, Walter Tetzlaff, Tomás Meroño, María Soledad Sáez, Amanda Yanez, Wilfried Le Goff, Javier Rosa, Anatol Kontush, Leonardo Gómez Rosso, Enrique R Soriano, Fernando Brites","doi":"10.1016/j.jacl.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.013","url":null,"abstract":"<p><strong>Background and aims: </strong>Tofacitinib, a Janus kinase inhibitor, has been associated with increased cardiovascular (CV) risk in rheumatoid arthritis (RA). This study evaluated tofacitinib's effects on lipid parameters and the impact of prior biological agents' therapy in RA patients.</p><p><strong>Methods: </strong>Thirty female RA patients starting tofacitinib were assessed at baseline and after 3 months. Clinical assessments, health assessment questionnaire (HAQ), disease activity score 28 (DAS28), inflammatory markers, lipid profile, oxidized low-density lipoprotein (LDL), activities of paraoxonase 1 (PON 1), lipoprotein-associated phospholipase A₂ (Lp-PLA₂), cholesteryl ester transfer protein (CETP), high-density lipoprotein (HDL) composition, and HDL functions (cholesterol efflux and free cholesterol uptake from triglyceride-rich lipoproteins [TGRL]) upon lipolysis were measured.</p><p><strong>Results: </strong>After 3 months, HAQ and DAS28 scores improved significantly. Total cholesterol (TC), HDL-C, non-HDL-C, and HDL capacity to acquire free cholesterol from TGRL increased, while enzyme activities and cholesterol efflux capacity remained unchanged. At baseline, patients with prior biological therapy (n = 19) had lower triglycerides, TC, non-HDL-C, and apolipoprotein (apo) B compared to biologic-naïve patients (n = 11). This group exhibited no lipid changes after tofacitinib, whereas biologic-naïve patients showed atherogenic increases in TC, LDL-C, non-HDL-C, apo B, Lp-PLA₂, and CETP, alongside beneficial increases in PON 1 activity.</p><p><strong>Conclusion: </strong>Tofacitinib improved disease activity and functional status in RA patients with minimal lipid changes. Patients previously treated with biological agents experienced no significant lipid alterations, while biologic-naïve patients showed atherogenic lipid changes and increased PON 1 activity. Prior biologic therapy may confer a more favorable CV profile before and after tofacitinib treatment.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the genetic background of familial hypercholesterolemia in a Turkish cohort and its clinical implications.","authors":"Erdem Kındış, Sevda Aygün, Banu Ertürk, Serkan Kabaçam, Naz Güleray Lafcı, Lale Tokgözoğlu, Mehmet Alikaşifoğlu","doi":"10.1016/j.jacl.2025.02.016","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.016","url":null,"abstract":"<p><strong>Objective: </strong>Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma cholesterol and an increased risk of early-onset coronary artery disease (CAD). FH has a complex genetic basis. Advances in molecular genetic techniques have deepened our understanding of FH, which is critical for accurate classification, CAD risk assessment, and optimized treatment strategies. This study aimed to evaluate the monogenic etiologies of FH and polygenic background as a possible cause of clinical FH phenotype and their relationship to clinical outcomes in a Turkish cohort.</p><p><strong>Methods: </strong>Patients were selected based on the Simon Broome Criteria. Various molecular techniques were employed, including Sanger sequencing, multiplex-ligation dependent probe amplification (MLPA), next-generation sequencing (NGS) panel analysis, and RNA-based studies. For the first time in a Turkish FH cohort, we calculated 6-single nucleotide polymorphism (SNP) and 12-SNP scores and compared them with a control group.</p><p><strong>Results: </strong>Multiple variants were identified, including 2 novel variants and a synonymous splice region variant in LDLR, which was shown to disrupt splicing through RNA analysis. The 6-SNP and 12-SNP scores displayed patterns consistent with other populations.</p><p><strong>Conclusion: </strong>Our findings suggest subtle differences in the monogenic etiology of FH in the Turkish population, with variant negative patients predominantly exhibiting polygenic background. Additionally, polygenic factors appear to influence the phenotype even in variant-positive individuals.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series.","authors":"Tyler J Schubert, Caroline deRichemond, Dean G Karalis, Laney K Jones","doi":"10.1016/j.jacl.2025.02.017","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.017","url":null,"abstract":"<p><p>The National Lipid Association (NLA) is currently conducting a study to improve the uptake of evidence-based guidelines into clinical practice through the deployment of case-based online learning modules to participating health systems nationwide. The Translating Evidence-based Approaches into optimal Care of High-risk atherosclerotic cardiovascular disease patients (TEACH-ASCVD) will evaluate the impact of electronic learning modules on clinician practices related to ASCVD management. In the design phase of TEACH-ASCVD, expert lipidologists created a series of 7 cases informed by recent guidelines intended to provide common clinical scenarios that evaluate participant knowledge of evidence-based practices for high-risk ASCVD and familial hypercholesterolemia. In this manuscript, we present 4 primary prevention-focused cases in high-risk patients and discuss pertinent clinical teaching points. These cases are intended for individuals with clinical lipidology training. We encourage lipidologists to disseminate this manuscript and utilize these cases as a teaching tool for nonlipid specialists to hone their knowledge of common clinical ASCVD risk management scenarios.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults.","authors":"Byung Jin Kim, Mi Yeon Lee, Eun Hye Cho, Youngwoo Jang, Jeonggyu Kang","doi":"10.1016/j.jacl.2025.02.014","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.014","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have investigated the relationship between remnant cholesterol (RC) and mortality outcomes in the general population, but the majority have focused on Western populations.</p><p><strong>Objective: </strong>This study aims to evaluate the association between RC and mortality-related outcomes in a relatively young and middle-aged Korean population.</p><p><strong>Methods: </strong>This cohort study included 268,219 participants (mean age, 38 years; 50.6% men) who were enrolled in the Kangbuk Samsung Health Study between 2003 and 2016. Fasting RC was calculated as total cholesterol minus low-density lipoprotein cholesterol minus high-density lipoprotein cholesterol.</p><p><strong>Results: </strong>The median RC was 0.47 mmol/L (18 mg/dL) and the prevalence of ≥1 mmol/L RC was 11.4%. During the median follow-up of 6.7 years, compared with the lowest quintile (RC <0.31 mmol/L), the hazard ratios (HRs) and 95% CIs for cardiovascular mortality were 1.95 [0.78, 4.84], 2.47 [1.03, 5.91], 2.39 [1.00, 5.72], and 2.84 [1.19, 6.78] in the second, third, fourth, and highest quintiles, respectively. The HRs for all-cause mortality in the third, fourth, and highest quintiles remained significant but were not significant for the risk of cancer mortality. Subgroup analyses showed that the high RC group with high-sensitivity C-reactive protein (hsCRP) or high lipoprotein(a) levels had more than 2-fold and 3-fold increased risks of cardiovascular mortality than the low RC group with low hsCRP or low lipoprotein(a) levels.</p><p><strong>Conclusion: </strong>High RC levels were significantly associated with an increased risk of cardiovascular and all-cause mortality, but not with cancer mortality. Specifically, high hsCRP and lipoprotein(a) levels weighted the risk association between high RC and cardiovascular mortality.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays-Steps toward standardization.","authors":"Alicia N Lyle, Elias N Flores, Clark C Coffman, Alex H Doty, Otoe Sugahara, Florian Kronenberg, L Renee Ruhaak, Christa M Cobbaert, Hubert W Vesper","doi":"10.1016/j.jacl.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.010","url":null,"abstract":"<p><strong>Background: </strong>Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular diseases (CVD). Recent clinical guidelines recommend measuring Lp(a); however, the lack of Lp(a) assay standardization presents challenges to using common clinical decision points. Assay standardization may minimize inter-assay variability. This improves consistency in CVD risk assessment and evaluations of Lp(a) therapeutic efficacy. Genetically determined size variations in the defining apolipoprotein(a) [apo(a)] protein contribute to inter-individual Lp(a) heterogeneity. Individuals who express 2 apo(a) isoforms have 2 sizes of apo(a) in circulation, further contributing to Lp(a) heterogeneity.</p><p><strong>Objective: </strong>The Centers for Disease Control and Prevention's Clinical Standardization Programs (CDC CSP) recently launched an Lp(a) standardization program based on the International Federation of Clinical Chemistry endorsed liquid-chromatography mass spectrometry-based reference measurement procedure (RMP). As part of this program, CDC CSP conducted an interlaboratory comparison study to evaluate current Lp(a) inter-assay variability and to investigate potential factors contributing to measurement variability.</p><p><strong>Methods: </strong>Eight clinical laboratories measured Lp(a) in 40 individual donor serum samples and 3 serum pools. Serum samples were immunophenotyped by Western blot analysis to determine Lp(a) isoform sizes. Sample concentrations were measured in duplicate over 2 independent runs.</p><p><strong>Results: </strong>Assay-specific Lp(a) measurements demonstrated good linear correlation with the RMP. Lp(a) inter-assay measurement variations ranged from 3.3% to 69.1% across individual samples; however, Lp(a) inter-assay coefficients of variation did not increase in a concentration-dependent manner and were not correlated with Lp(a) isoform sizes.</p><p><strong>Conclusion: </strong>This study provides new insights into Lp(a) inter-assay variability and assay performance in clinical laboratories that will guide future standardization efforts.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of lipoprotein(a) and coronary artery calcium with atherosclerotic cardiovascular disease.","authors":"Byung Jin Kim, Jeonggyu Kang","doi":"10.1016/j.jacl.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.007","url":null,"abstract":"<p><strong>Background: </strong>A combined evaluation of the associations of lipoprotein(a) (LP[a]) and coronary artery calcium score (CACS) with atherosclerotic cardiovascular disease (ASCVD) has not been conducted in the Asian population.</p><p><strong>Objective: </strong>We explored whether elevated LP(a) levels and CACS are independently and jointly associated with ASCVD.</p><p><strong>Methods: </strong>This cross-sectional study included 44,354 participants (mean age 40.6 years, 72.8% male) from the Kangbuk Samsung Health Study, conducted between March 2010 and December 2019, who were tested for LP(a) and CACS. High LP(a) was defined as LP(a) ≥120 nmol/L, and CACS categories were divided as CACS = 0 vs CACS > 0. ASCVD was identified as physician-diagnosed or -treated angina pectoris, myocardial infarction, or ischemic stroke.</p><p><strong>Results: </strong>The prevalence of high LP(a), CACS >0, and ASCVD was 11.9%, 15.7%, and 1.1%, respectively. Multivariable regression analyses indicated that high LP(a) and CACS >0 were independently associated with prevalent ASCVD (odds ratio [95% CI], 1.36 [1.02, 1.81] and 1.79 [1.40, 2.30], respectively). Compared with individuals with low LP(a)/CACS = 0, those with high LP(a)/CACS > 0 had the highest OR for ASCVD (2.40 [1.58, 3.63]), as did those with low LP(a)/CACS > 0 (1.79 [1.38, 2.33]). However, high LP(a)/CACS = 0 did not significantly increase the OR for ASCVD (1.36 [0.90, 2.05]).</p><p><strong>Conclusion: </strong>High LP(a) levels and the presence of CAC are independently associated with ASCVD. Given that both markers were additively associated with ASCVD when elevated, more aggressive management to reduce cardiovascular risk may be warranted. Longitudinal studies are necessary to clarify the combined causal relationship between these 2 markers and cardiovascular events in the Asian population.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and prevalence of severe hypertriglyceridemia in Pakistan: A five-year analysis (2019-2023).","authors":"Quratul Ain, Madeeha Khan, Amjad Nawaz, Hijab Batool, Mohammad Iqbal Khan, Muhammad Ajmal, Fouzia Sadiq","doi":"10.1016/j.jacl.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.009","url":null,"abstract":"<p><strong>Background: </strong>Severe hypertriglyceridemia (HTG) is associated with increased risk of cardiovascular disease and acute pancreatitis. Previously, there were no studies or data available from Pakistan regarding this condition. This study aimed to analyze the trends and prevalence of severe HTG in Pakistan over a 5-year period from 2 healthcare centers.</p><p><strong>Methods: </strong>A retrospective analysis of laboratory data from 2 major healthcare centers across Pakistan's 4 provinces was conducted. Demographic information and lipid profiles of patients were collected. HTG was categorized as HTG (≥150 mg/dL), mild HTG (150-199), moderate HTG (200-999), severe HTG (1000-1999 mg/dL), and very severe HTG (≥2000 mg/dL).</p><p><strong>Results: </strong>A study of 552,719 individuals (mean age 45.9 ± 12.6 years, 58.1% males and 41.9% females) revealed that 53.7% (1:2) were hypertriglyceridemic. Severe HTG was observed in 0.3% (1:286) of the population, while very severe HTG was found in 0.1% (1:861). Both severe and very severe HTG were more prevalent in males, individuals aged under 18 years, and those aged 36 to 45 years. Very severe HTG was most prevalent in Khyber Pakhtunkhwa (0.2%). Patients with severe HTG presented with mean triglyceride levels of 1308.2 ± 254.7 mg/dL, while those with very severe HTG showed levels of 3293.0 ± 1889.9 mg/dL.</p><p><strong>Conclusion: </strong>This study revealed that 53.7% of the population had HTG, with severe and very severe HTG affecting 0.3% and 0.1%, respectively. Males, younger individuals, and residents of Khyber Pakhtunkhwa had higher prevalence. These findings emphasize the need for targeted interventions in high-risk groups.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases-Insights from a preventive cardio-rheuma clinic.","authors":"Eli P Sollerud, Eirik Ikdahl, Anne Kerola, Joe Sexton, Anne Grete Semb","doi":"10.1016/j.jacl.2025.02.002","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.002","url":null,"abstract":"<p><strong>Background: </strong>A disparity exists between adherence to guideline recommendations for cardiovascular (CV) prevention and achieving low-density lipoprotein cholesterol (LDL-C) goals in clinical practice. The aim was to assess the effectiveness of lipid-lowering therapies in high- and very high-risk patients with coexisting inflammatory joint diseases (IJD).</p><p><strong>Methods: </strong>This quality assurance project included all consecutive patients with IJD referred to a CV risk evaluation between 2019 and 2024 to a single clinic in Norway. According to guidelines, patients categorized as high- or very high-risk of atherosclerotic CV disease received lipid-lowering therapies. The patients were followed every 1 to 3 months for monitoring and evaluation of LDL-C levels.</p><p><strong>Results: </strong>In total, 264 of 414 referred patients with IJD were classified as having high (n = 25) or very high (n = 239) risk and 229 patients completed treatment. Total cholesterol and LDL-C from baseline to final consultation were significantly reduced (mean ± SD) by 1.88 ± 1.1 and 1.81 ± 1.1 mmol/L, respectively. The median LDL-C at the end of follow-up was 1.6 (IQR: 1.1-1.9) mmol/L and 1.4 (IQR: 1.2-1.5) mmol/L for high- and very high-risk patients, with median reductions of 59% and 56%, respectively. At the end of follow-up, 70% of the high-risk patients were on combination lipid-lowering therapy.</p><p><strong>Conclusions: </strong>Significant reductions in LDL-C levels are achievable in a large proportion of high-risk patients with IJD. These findings suggest that combination therapy, frequent monitoring and individualized treatment strategies, including lifestyle management, may play a crucial role in CV prevention in high-risk populations.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and biochemical spectrum of APOB-related hypobetalipoproteinemia: Insights from a retrospective cohort study.","authors":"İlknur Sürücü Kara, Engin Köse, Hatice Mutlu, Aslıhan Sanrı, Patrizia Tarugi, Fatma Tuba Eminoğlu","doi":"10.1016/j.jacl.2025.02.003","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.003","url":null,"abstract":"<p><strong>Background: </strong>APOB-related familial hypobetalipoproteinemia (APOB-FHBL), the most common form of primary hypobetalipoproteinemia, often leaves heterozygous patients asymptomatic. This study aims to provide updated insights into the complications observed in heterozygous and homozygous APOB-FHBL patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 15 patients (53.3% female) from 7 families diagnosed with FHBL and followed in a metabolic clinic. Demographic, laboratory, clinical, and genetic data were reviewed.</p><p><strong>Results: </strong>Patients were followed for an average of 4.5 ± 4.1 years. The median levels were as follows: low-density lipoprotein cholesterol (LDL-C; 25.7 ± 10.5 mg/dL), apolipoprotein B (ApoB; 0.3 ± 0.1 g/L), aspartate aminotransferase (AST; 40.1 ± 22.5 U/L), alanine aminotransferase (ALT; 43.0 ± 38.3 U/L), and alpha feto-protein (AFP; 1.3 ± 0.7 ng/mL). Elevated AST and ALT levels were observed in 20.0% and 26.7% of cases, respectively. Vitamin E deficiency was identified in 26.7%, vitamin A deficiency in 13.3%, and vitamin D insufficiency in 66.7% of cases. Liver ultrasonography revealed hepatosteatosis in 73.3% of patients. Additionally, the study identified 5 novel APOB gene variants. Among the families, 3 had members who died due to complications related to viral infections (COVID-19, hepatitis B virus) or hepatocellular carcinoma (HCC) resulting from chronic liver disease.</p><p><strong>Conclusion: </strong>Patients with elevated transaminase levels or hepatosteatosis should undergo a lipid profile assessment. LDL-C levels below 50 mg/dL require further evaluation, including ApoB and fat-soluble vitamin levels. Monoallelic APOB variants are linked to poor outcomes due to deficiencies in vitamins A, E, and D, as well as an increased risk of HCC. Early recognition and regular monitoring are essential for the effective management of APOB-FHBL patients.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of lipid management practices for secondary atherosclerotic cardiovascular disease prevention in abdominal solid organ transplant recipients.","authors":"Kennedy Concannon, Zachary Bentz, Sarah Kokosa, Holly Berry, Jennifer Byrns","doi":"10.1016/j.jacl.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.jacl.2025.02.004","url":null,"abstract":"<p><strong>Background: </strong>High-intensity HMG-CoA reductase inhibitors (statins) are recommended for secondary atherosclerotic cardiovascular disease (ASCVD) prevention. Solid organ transplant (SOT) recipients are at an increased risk of ASCVD events. This study evaluated if abdominal SOT recipients who experienced an ASCVD event prior to transplant received guideline-directed pharmacotherapy for secondary ASCVD prevention post-transplant.</p><p><strong>Methods: </strong>Single-center, retrospective, cohort study that evaluated lipid-lowering therapy prescribing practices in SOT recipients transplanted at Duke University Hospital. The primary objective was the percentage of patients receiving a high-intensity statin regimen during the first year post-transplant. Secondary objectives included reason for change in statin therapy, other lipid-lowering medications prescribed, percentage of patients who had lipid panel(s) drawn, safety of statin therapy, and the incidence of recurrent ASCVD or death secondary to an ASCVD event within the first year post-transplant.</p><p><strong>Results: </strong>Sixty-three transplant patients were included, 46 (73%) received a kidney, 12 (19%) a liver, and 5 (7.9%) a multi-organ transplant. Twenty-four patients (38.1%) were maintained on a high-intensity statin during the first year post-transplant. Reason for statin dose change included elevated lipids (35.3%), statin-related safety event (11.8%), and undocumented reason (52.9%). Statins were well tolerated. Two (3.2%) patients experienced a recurrent myocardial infarction within the first year post-transplant.</p><p><strong>Conclusion: </strong>Less than half of the abdominal transplant patients were maintained on guideline-directed high-intensity statin therapy for secondary ASCVD prevention at 1 year post-transplant. Our findings demonstrate an opportunity to optimize the prescribing practices of lipid-lowering therapy following abdominal transplant in a high cardiovascular risk population.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}